{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-244963","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2021-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.119166+00:00","generated_at":"2026-06-29T10:59:01.737726+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Corcept Therapeutics appoints William Guyer as CDO; CMO Andreas Grauer departs","bullets":["Andreas Grauer separated as CMO effective Aug 10, 2021, becomes senior medical advisor to assist transition.","William Guyer, formerly SVP at Gilead Sciences, appointed CDO effective Aug 16, 2021.","Guyer brings ~30 years of experience; led global Medical Affairs at Gilead, involved in multiple drug launches.","Separation agreement provides Grauer one-year salary continuation, COBRA coverage, and quarterly housing allowance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-244963","json":"https://secwatch.observer/filing/0001193125-21-244963.json","markdown":"https://secwatch.observer/filing/0001193125-21-244963.md","text":"https://secwatch.observer/filing/0001193125-21-244963.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312521244963/0001193125-21-244963-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312521244963/d552481d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T10:59:01.737726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"391091c901","claim":"Andreas Grauer changed role as senior medical advisor at CORCEPT THERAPEUTICS INC.","evidence_excerpt":"On August 10, 2021, Andreas Grauer, M.D. separated from his position as Chief Medical Officer of Corcept Therapeutics Incorporated (the “Company”). Dr. Grauer has agreed to serve as a senior medical advisor to the Company to assist with its development programs and to help transition his responsibilities to the Company’s Chief Development Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000119312521244963/0001193125-21-244963-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"agreed to serve as senior medical advisor"},{"label":"Role","value":"senior medical advisor"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}